Electronic Patient Self-Reported Outcomes to Improve Cancer Management and Patient Experiences (ePRIME)
Electronic Patient Self-Reported Outcomes to Improve Cancer Management and Patient Experiences: Implement the System for Remote Monitoring of Cancer Patients in Remission
Descripción general del estudio
Descripción detallada
Background Improvements in cancer treatment have led to an increasing number of patients being cured or in remission, but they are followed up to detect recurrence, manage persistent symptoms and late treatment effects. With growing survivors, traditional hospital follow-up is not sustainable. New models of follow-up care are needed.
Aim To develop and establish the feasibility of introducing a new electronic care pathway/system for remote monitoring ovarian cancer patients in remission.
Methods An existing online patient symptom reporting system will be extended for use in remote follow-up. A tracking program will be developed and IT systems integrated in the local hospitals.
Development Phase:
a) Scoping literature review of existing validated symptom measures. b) Consultation with expert groups to establish choice of questions, relevant symptoms, timing/frequency for monitoring. c) Interviews with patients and clinicians to explore current pathway and redesign.
Audit of usual care phase In this phase consecutive eligible ovarian, fallopian tube, primary peritoneal, endometrial or female genital (not otherwise specified) cancer patients (on completion of their first/second line of treatment) will be approached and data on clinical outcomes collected at the routine 3 monthly outpatient appointments for 12 months and PROMs collected 6 monthly. We aim to recruit around 60 patients.
Pilot Intervention phase In the intervention group the feasibility of the re-designed care pathway (intervention) will be piloted in a separate group of eligible ovarian, fallopian tube, primary peritoneal, endometrial or female genital (not otherwise specified) cancer patients. The patients approached will be a mixture of those who are entering follow-up after recently completing their first/second line treatment, and those who have already been attending for some time (months/years) for routine follow-up after their first/second line treatment. We aim to recruit around 60 patients. Consenting patients will be reminded to use the online system every 3 months and have a mandatory blood test by their GP/local hospital. Information will be available for the clinical teams to access electronically. Patients will always have the option to choose to speak or see their 'key clinician'. Virtual clinics will be held for key clinicians to review and respond to remote monitoring data. Clinical and patient outcomes will be collected for a 6-12 month period (this timeframe is dependent on the date of study entry and the funding period remaining). Following the pilot intervention period, 10 patients (or more if deemed necessary) and 6 clinicians will also be interviewed.
Outcomes
- Develop a new electronic care pathway/system for remote monitoring patients in remission
- Obtain initial data on clinical and patient feasibility.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
West Yorkshire
-
Leeds, West Yorkshire, Reino Unido, LS97TF
- St James University Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Adult patients (aged 18 years or over) attending St James' University Hospital Bexley Wing, Bradford Teaching Hospitals NHS Foundation Trust, Calderdale & Huddersfield NHS Foundation Trust, and Airedale NHS Foundation Trust with stage 2-4 ovarian/fallopian/peritoneal/endometrial cancer in remission following the end of first or second line chemotherapy or end of maintenance Avastin/Bevacizumab (where indicated)
- Patients may have recently completed treatment or already been on routine clinic-based face-to-face follow-up at the time of recruitment into the pilot intervention phase
- Able and willing to give informed consent
- Able to read and understand English
- Access to the internet
Exclusion Criteria:
- Exhibiting overt psychopathology/cognitive dysfunction
- Taking part in other clinical trials involving the completion of extensive patient reported outcome or quality of life measures or requiring scheduled face-to-face clinical outpatient appointments (Intervention group only)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Investigación de servicios de salud
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Sin intervención: Audit phase
In the audit-phase, a group of 59 patients will be recruited and followed over a 12 month period.
Data will be collected on clinical and patient outcomes in an audit in order to be able to compare to the intervention (after-phase) group.
|
|
|
Experimental: Intervention (pilot-phase)
In the pilot-phase, a group of 59 patients will be recruited and followed over a 6-12 month period.
Patients in this group will be assigned to the new remote monitoring follow-up pathway (ePRIME), whereby instead of attending routine outpatient appointments they are monitored remoted via a online symptom monitoring questionnaire and related clinical tests undertaken remotely.
All information is collated in the patient's electronic patient record, and clinicians will review/respond to the data as necessary.
|
ePRIME is an remote monitoring pathway that includes an online system for patients to self-report symptoms and AE following cancer treatments.
ePRIME allows AE reporting from home and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care.
In addition the system is capable of generating alerts for serious symptoms to the relevant clinical team and providing patient advice on managing mild and moderate symptoms.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of patients recruited / Number of patients approached (=consent rate)
Periodo de tiempo: Baseline
|
Number of patients recruited and number of patients approached will be logged by research team during recruitment (including reasons for non-recruitment)
|
Baseline
|
|
Number of participant withdrawals
Periodo de tiempo: 12 months
|
Number of participant withdrawals will be logged by research team at the time of any withdrawals
|
12 months
|
|
Reasons for participant withdrawals
Periodo de tiempo: 12 months
|
Reasons for withdrawal will be assessed via case record form completed by researcher with the participant at time of withdrawal and collated at the end of the study
|
12 months
|
|
Number of participants with self-reported symptom data (questionnaire) at 3 months
Periodo de tiempo: 3 months
|
Patients will be reminded to complete an electronic questionnaire about their symptoms at 3 months
|
3 months
|
|
Number of participants with self-reported symptom data (questionnaire) at 6 months
Periodo de tiempo: 6 months
|
Patients will be reminded to complete an electronic questionnaire about their symptoms at 6 months
|
6 months
|
|
Number of participants with self-reported symptom data (questionnaire) at 9 months
Periodo de tiempo: 9 months
|
Patients will be reminded to complete an electronic questionnaire about their symptoms at 9 months
|
9 months
|
|
Number of participants with self-reported symptom data (questionnaire) at 12 months
Periodo de tiempo: 12 months
|
Patients will be reminded to complete an electronic questionnaire about their symptoms at 12 months
|
12 months
|
|
Patient acceptability (questionnaire/interviews)
Periodo de tiempo: 12 months
|
Patient acceptability explored through end-of-study questionnaires and interviews
|
12 months
|
|
Clinician acceptability (questionnaire/interviews)
Periodo de tiempo: 12 months
|
Clinician acceptability explored through end-of-study questionnaires and interviews
|
12 months
|
Colaboradores e Investigadores
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- L392 (gynae)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .